| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Selling, general and administrative | NaN | 7,610 | 7,809 | |
| Revenue | 495 | 753 | 301 | |
| Cost of goods sold | 2,038 | 260 | 213 | |
| Research and development | 19,462 | 17,273 | 22,006 | |
| General and administrative | 7,930 | NaN | NaN | |
| Total operating expenses | 29,430 | 25,143 | 30,028 | |
| Loss from operations | -28,935 | -24,390 | -29,727 | |
| Interest income | 330 | 590 | 832 | |
| Change in fair value of contingent earnout liability | -4,732 | -4,893 | 5,470 | |
| Interest expense | 2,271 | 2,612 | 2,545 | |
| Change in fair value of derivatives | 8,525 | 4,009 | -748 | |
| Total other income, net | 11,316 | 6,880 | -7,931 | |
| Net (loss) income and comprehensive (loss) income | -17,619 | -17,510 | -37,658 | |
| Basic EPS | -0.09 | -0.11 | -0.24 | |
| Diluted EPS | -0.09 | -0.11 | -0.24 | |
| Basic Average Shares | 197,846,786 | 158,313,290 | 155,437,281 | |
| Diluted Average Shares | 197,846,786 | 158,313,290 | 155,437,281 | |
Humacyte, Inc. (HUMAW)
Humacyte, Inc. (HUMAW)